G1 cell-cycle control and cancer

Nature

Volumn 432, Issue 7015, 2004, Pages 298-306

  Massagué, Joan ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SIGNAL PROCESSING; TUMORS;

REPRODUCTIVE CYCLE; SIGNALLING NETWORKS; STRESS MANAGEMENT;

CELLS;

CYCLINE; PHOSPHOTRANSFERASE; PROTEIN BCL 2; PROTEIN BCL XL; SMAD PROTEIN; TARGET OF RAPAMYCIN KINASE;

CANCER;

CANCER; CANCER GROWTH; CELL CYCLE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL DIVISION; CELL FATE; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CYTOSTASIS; DNA DAMAGE; DNA REPLICATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVIEW; STEM CELL;

ANIMALS; CELL CYCLE; DNA DAMAGE; G1 PHASE; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 9244239811     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature03094     Document Type: Review

References (98)

1. Morgan, D. O. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol. 13, 261-291 (1997).
2. Murray, A. W. Recycling the cell cycle: cyclins revisited. Cell 116, 221-234 (2004).
3. Kelly, T. J. & Brown, G. W. Regulation of chromosome replication. Annu. Rev. Biochem. 69, 829-880 (2000).
4. Prasanth, S. G., Mendez, J., Prasanth, K. V. & Stillman, B. Dynamics of pre-replication complex proteins during the cell division cycle. Phil. Trans. R. Soc. Lond. B 359, 7-16 (2004).
5. Geng, Y. et al. Cyclin E ablation in the mouse. Cell 114, 431-443 (2003).
6. Ortega, S. et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nature Genet. 35, 25-31 (2003).
7. Sears, R. C. & Nevins, J. R. Signaling networks that link cell proliferation and cell fate. J. Biol. Chem. 277, 11617-11620 (2002).
8. Stevaux, O. & Dyson, N. J. A revised picture of the E2F transcriptional network and RB function. Curr. Opin. Cell Biol. 14, 684-691 (2002).
9. Lipinski, M. M. & Jacks, T. The retinoblastoma gene family in differentiation and development. Oncogene 18, 7873-7882 (1999).
10. Sherr, C. J. & Roberts, J. M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501-1512 (1999).
11. Sherr, C. J. Principles of tumor suppression. Cell 116, 235-246 (2004).
12. Geng, Y. et al. Rescue of cyclin D1 deficiency by knockin cyclin E. Cell 97, 767-777 (1999).
13. Kozar K et al. Mouse development and cell proliferation in the absence of d cyclins. Cell 118, 477-491, (2004).
14. Malumbres M. et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 118, 493-504, (2004).
15. Pavletich, N. P. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J. Mol. Biol. 287, 821-828 (1999).
16. Blain, S. W., Scher, H. I., Cordon-Cardo, C. & Koff, A. p27 as a target for cancer therapeutics. Cancer Cell 3, 111-115 (2003).
17. Montagnoli, A. et al. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev. 13, 1181-1189 (1999).
18. Reed, S. I. Ratchets and clocks: the cell cycle, ubiquitylation and protein turnover. Nature Rev. Mol. Cell. Biol. 4, 855-864 (2003).
19. Bashir, T., Dorrello, N. V., Amador, V., Guardavaccaro, D. & Pagano, M. Control of the SCF (Skp2-Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase. Nature 428, 190-193 (2004).
20. Wei, W. et al. Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature 428, 194-198 (2004).
21. Petronczki, M., Siomos, M. F. & Nasmyth, K. Un menage a quatre: the molecular biology of chromosome segregation in meiosis. Cell 112, 423-440 (2003).
22. Rape, M. & Kirschner, M. W. Autonomous regulation of the anaphase-promoting complex couples mitosis to S-phase entry. Nature (in the press).
23. Hsu, J. Y. et al. E2F-dependent accumulation of hEmil regulates S phase entry by inhibiting APC (Cdh1). Nature Cell Biol. 4, 358-366 (2002).
24. Yu, Q., Geng, Y. & Sicinski, P. Specific protection against breast cancers by cyclin D1 ablation. Nature 411, 1017-1021 (2001).
25. Pawson, T. Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell 116, 191-203 (2004).
26. Schlessinger, J. & Lemmon, M. A. SH2 and PTB domains in tyrosine kinase signaling. Sci. STKE 191, RE12 (2003).
27. Downward, J. Targeting RAS signalling pathways in cancer therapy. Nature Rev. Cancer 3, 11-22 (2003).
28. Coleman, M. L., Marshall, C. J. & Olson, M. F. RAS and RHO GTPases in G1-phase cell-cycle regulation. Nature Rev. Mol. Cell Biol. 5, 355-366 (2004).
29. Giancotti, F. G. & Tarone, G. Positional control of cell fate through joint integrin/receptor protein kinase signaling. Annu. Rev. Cell Dev. Biol. 19, 173-206 (2003).
30. Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature Rev. Cancer 2, 489-502 (2002).
31. Tran, H., Brunet, A., Griffith, E. C. & Greenberg, M. E. The many forks in FOXO's road. Sci. STKE 172, RE5 (2003).
32. Gschwind, A., Fischer, O. M. & Ullrich, A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nature Rev. Cancer 4, 362-370 (2004).
33. Sawyers, C. L. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev. 17, 2998-3010 (2003).
34. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
35. Noble, M. E., Endicott, J. A. & Johnson, L. N. Protein kinase inhibitors: insights into drug design from structure. Science 303, 1800-1805 (2004).
36. Arteaga, C. L. & Baselga, J. Tyrosine kinase inhibitors; why does the current process of clinical development not apply to them? Cancer Cell 5, 525-531 (2004).
37. Ferrara, N., Hillan, K. J., Gerber, H. P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Rev. Drug. Discov. 3, 391-400 (2004).
38. Chiosis, G. L. B., Huezo, H., Solit, D., Basso, A. & Rosen, N. Development of purine-scaffold small molecule inhibitors of Hsp90. Curr Cancer Drug Targets 3, 371-376 (2003).
39. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
40. Maher, E. A. et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 15, 1311-1333 (2001).
41. Pao, W. et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib (Iressa®) and erlotinib (Tarceva TM). Proc. Natl Acad. Sci. USA 101, 13306-13311 (2004).
42. Danial, N. N. & Korsmeyer, S. J. Cell death: critical control points. Cell 116, 205-219 (2004).
43. Ashkenazi, A. & Dixit, V. M. Death receptors: signaling and modulation. Science 281, 1305-1308 (1998).
44. Jiang, X. & Wang, X. Cytochrome C-mediated apoptosis. Ann. Rev. Biochem. 73, 87-106 (2004).
45. Davis, R. J. Signal transduction by the JNK group of MAP kinases. Cell 103, 239-252 (2000).
46. Kolesnick, R. & Fuks, Z. Radiation and ceramide-induced apoptosis. Oncogene 22, 5897-3906 (2003).
47. Cory, S. & Adams, J. M. The Bcl2 family: regulators of the cellular life-or-death switch. Nature Rev. Cancer 2, 647-656 (2002).
48. Hu, M. C. et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117, 225-237 (2004).
49. Bonni, A. et al. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286, 1358-1362 (1999).
50. Barradas, M., Monjas, A., Diaz-Meco, M. T., Serrano, M. & Moscat, J. The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression. EMBO J. 18, 6362-6369 (1999).
51. Bjornsti, M. A. & Houghton, P. J. The TOR pathway: a target for cancer therapy. Nature Rev. Cancer 4, 335-348 (2004).
52. Lizcano, J. M. et al. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 23, 833-843 (2004).
53. Shaw, R. J. et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6, 91-99 (2004).
54. Holland, E. C., Sonenberg, N., Pandolfi, P. P. & Thomas, G. Signaling control of mRNA translation in cancer pathogenesis. Oncogene 23, 3138-3144 (2004).
55. Rajasekhar, V. K. et al. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol. Cell 12, 889-901 (2003).
56. Wendel et al. Survival signaling by Akt and eIF4E in oncogenetics and cancer therapy. Nature 428, 332-337 (2004).
57. Ruggero, D. et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nature Med. 10, 484-486 (2004).
58. Cohen, P. & Frame, S. The renaissance of GSK3. Nature Rev. Mol. Cell Biol. 2, 769-776 (2001).
59. Jope, R. S. & Johnson, G. V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 29, 95-102 (2004).
60. Grandori, C., Cowley, S. M., James, L. P. & Eisenman, R. N. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu. Rev. Cell Dev. Biol. 16, 653-699 (2000).
61. Wanzel, M., Herold, S. & Eilers, M. Transcriptional repression by Myc. Trends Cell Biol. 13, 146-150 (2003).
62. Seoane, J., Le, H. V. & Massagué, J. Myc suppression of the p21 (Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419, 729-734 (2002).
63. Pelengaris, S., Khan, M. & Evan, G. c-MYC: more than just a matter of life and death. Nature Rev. Cancer 2, 764-776 (2002).
64. Siegel, P. M. & Massagué, J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nature Rev. Cancer 3, 807-821 (2003).
65. Shi, Y. & Massagué, J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685-700 (2003).
66. Seoane, J., Le, H. V., Shen, L., Anderson, S. A. & Massagué, J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117, 211-23 (2004).
67. Accili, D. & Arden, K. C. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117,421-426 (2004).
68. Derynck, R., Akhurst, R. J. & Balmain, A. TGF-beta signaling in tumor suppression and cancer progression. Nature Genet. 29, 117-129 (2001).
69. Roberts, A. B. & Wakefield, L. M. The two faces of transforming growth factor beta in carcinogenesis. Proc. Natl Acad. Sci. USA 100, 8621-8623 (2003).
70. Michael, D. & Oren, M. The p53 and Mdm2 families in cancer. Curr. Opin. Genet. Dev. 12, 53-59 (2002).
71. Sancar, A., Lindsey-Boltz, L. A., Unsal-Kaccmaz, K. & Linn, S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 73, 39-85 (2004).
72. Vousden, K. H. & Lu, X. Live or let die: the cell's response to p53. Nature Rev. Cancer 2, 594-604 (2002).
73. Flores, E. et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416, 560-564 (2002).
74. Senoo, M., Manis, J. P., Alt, F. W. & McKeon, E p63 and p73 are not required for the development and p53-dependent apoptosis of T cells. Cancer Cell 6, 85-89 (2004).
75. Brooks, C. L. & Gu, W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol. 15, 164-171 (2003).
76. Lowe, S. W. & Sherr, C. J. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Dev. 13, 77-83 (2003).
77. Brunet, A. et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303, 2011-2015 (2004).
78. Motta, M. C. et al. Mammalian SIRT1 represses forkhead transcription factors. Cell 116, 551-563 (2004).
79. Arden, K. C. FoxO: linking new signaling pathways. Mol. Cell 14, 416-418 (2004).
80. So, C. W. & Cleary, M. L. MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function. Mol. Cell. Biol. 22, 6542-6552 (2003).
81. Ruzinova, M. B. & Benezra, R. Id proteins in development, cell cycle and cancer. Trends Cell Biol. 13,410-418 (2003).
82. Ying, Q. L., Nichols, J., Chambers, I. & Smith, A. BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell 115, 281-292 (2003).
83. Jacobs, J. J. et al. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF Genes Dev. 13, 2678-2690 (1999).
84. Park, I. K. et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423, 302-305 (2003).
85. Lessard, J. & Sauvageau, G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423, 255-260 (2003).
86. Owens, D. M. & Watt, F. M. Contribution of stem cells and differentiated cells to epidermal tumours. Nature Rev. Cancer 3, 444-451 (2003).
87. Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001).
88. Jamieson, C. H. et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 351, 657-667 (2004).
89. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad. Sci. USA 100, 3983-3988 (2003).
90. van de Wetering, M. et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111, 241-250 (2002).
91. Lum, L. & Beachy, P. A. The Hedgehog response network: sensors, switches, and routers. Science 304, 1755-1759 (2004).
92. Oliver, T. G. et al. Transcriptional profiling of the Sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors. Proc. Natl Acad. Sci. USA 100, 7331-7336 (2003).
93. Kerney, A. M., Cole, H. D. & Rowitch, D. H. Nmyc upregulation by sonic hedgehog signalling promotes proliferation in developing cerebellar granule neurone precursors. Development 130, 15-28 (2003).
94. Grady, W. M. & Markowitz, S. D. Genetic and epigenetic alterations in colon cancer. Annu. Rev. Genomics Hum. Genet. 3, 101-128 (2002).
95. Berman, D. M. et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425, 846-851 (2003).
96. Thayer, S. P. et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425, 851-856 (2003).
97. Karhadkar, S. S. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431, 707-712 (2004).
98. Shah, N. P. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399-401 (2004).